Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.55 |
| ▸ | MLNR | O43193 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24950321 | 0.95 | ESR1 (0.54) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL14324257 | 0.94 | ESR1 (0.66) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL19959084 | 0.93 | ESR1 (0.52) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL27438189 | 0.93 | ESR1 (0.62) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL19959082 | 0.92 | ESR1 (0.61) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL18149883 | 0.91 | ESR1 (0.53) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL19949697 | 0.91 | ESR1 (0.60) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL18149862 | 0.90 | ESR1 (0.61) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL30782456 | 0.88 | ESR1 (0.57) | ESR1ESR2MLNRABCB11NR3C1 | |
| SCHEMBL27480940 | 0.88 | ESR1 (0.64) | ESR1ESR2MLNRABCB11NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210040081-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-10865202-B2 | Indole derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190233408-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. | 2019-08-01 | — | — | US | disclosed |
| EP-3512842-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053354-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053354-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040081-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885MLNR 578/4885 |
| US-10865202-B2 | Indole derivatives as estrogen receptor degraders | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885MLNR 578/4885 |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885MLNR 578/4885 |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885MLNR 578/4885 |
| US-20190233408-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885MLNR 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.